NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma. (2022)

First Author: Adler AI
Attributed to:  Calibration of multiple treatment comparisons using individual patient data funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(22)00301-0

PubMed Identifier: 35988573

Publication URI: http://europepmc.org/abstract/MED/35988573

Type: Journal Article/Review

Volume: 10

Parent Publication: The Lancet. Respiratory medicine

Issue: 10

ISSN: 2213-2600